FDA Approves New Diabetic Macular Edema Treatment Option

The FDA has approved Lucentis (ranibizumab injection) 0.3 mg prefilled syringe as a new method for administering treatment for diabetic macular edema and diabetic retinopathy.

Lucentis 0.3 mg was originally approved for the treatment of all forms of diabetic retinopathy in individuals with or without diabetic macular edema in April 2017.
____________________________________________________________________________________________

RELATED CONTENT
5 Questions With Dr Theodore Leng: Diabetic Retinopathy, Anti-VEGF, and Laser Treatments
FDA Approves New Treatment for Diabetic Retinopathy
____________________________________________________________________________________________

The prefilled syringe is packaged in a single-use, sterile, sealed tray and will be available in the second quarter of 2018.

The most common eye-related adverse effects associated with Lucentis are redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infection, headache, lung infections, and nausea.

—Michael Potts

Reference:

FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy [press release]. Roche. https://www.roche.com/investors/updates/inv-update-2018-03-22.htm.